Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00052910 · ClinicalTrials.gov registry record · Phase 3
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
A Phase 3 study of Gastric Cancer and Esophageal Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 546
- Enrollment target
- 20
- Study locations
NCT00052910 is a Phase 3 study of Gastric Cancer and Esophageal Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 546 participants, above the 316-participant average among 153 other Gastric Cancer trials with a reported enrollment target (73% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT00052910, a Phase 3 study of Gastric Cancer and Esophageal Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 546 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy after surgery may kill any remaining tumor cells following surgery. It is not yet known which chemotherapy and radiation therapy regimen is more effective in treating stomach or esophageal cancer. PURPOSE: Randomized phase III trial to compare two different chemotherapy and radiation therapy regimens in treating patients who have undergone surgery for stomach or esophageal cancer.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG fluorouracil
- DRUG epirubicin hydrochloride
- DRUG leucovorin calcium
- RADIATION radiation therapy
Study Locations (20)
California
- Kaiser Permanente - Deer Valley - Antioch
- Providence Saint Joseph Medical Center - Burbank - Burbank
- East Bay Radiation Oncology Center - Castro Valley
- Eden Medical Center - Castro Valley
- Valley Medical Oncology Consultants - Castro Valley - Castro Valley
- City of Hope Comprehensive Cancer Center - Duarte
- Kaiser Permanente - Fremont - Fremont
- Valley Medical Oncology - Fremont
- Glendale Memorial Hospital Comprehensive Cancer Center - Glendale
- Kaiser Permanente Medical Center - Hayward - Hayward
- Rebecca and John Moores UCSD Cancer Center - La Jolla
- Contra Costa Regional Medical Center - Martinez
- Memorial Medical Center - Modesto
Arkansas
- Hembree Mercy Cancer Center at St. Edward Mercy Medical Center - Fort Smith
- Ben E. Owens Cancer Treatment Center at St. Bernard's Medical Center - Jonesboro
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Alabama
- Regional Medical Center - Anniston
- Providence Cancer Center at Providence Hospital - Mobile
Arizona
- Mayo Clinic Scottsdale - Scottsdale
- Arizona Cancer Center at University of Arizona Health Sciences Center - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 546 participants |
| Start Date | 2002-12 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00052910
The ClinicalTrials.gov registry entry for NCT00052910 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 546 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 316-participant average among 153 other Gastric Cancer trials with a reported enrollment target (73% higher). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 5 interventions - of which cisplatin is the first listed.
NCT00052910 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arkansas, Alabama.
Frequently Asked Questions
What is clinical trial NCT00052910 about?
NCT00052910 is a clinical study titled "Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy after surgery may kill any remaining tumor cells following surgery. I...
What is the current status of trial NCT00052910?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 546 participants. The study started on 2002-12. Estimated completion is 2016-12.
What conditions does trial NCT00052910 study?
This clinical trial studies the following conditions: Gastric Cancer, Esophageal Cancer.
What interventions are being tested in trial NCT00052910?
The interventions under investigation include: cisplatin (DRUG), fluorouracil (DRUG), epirubicin hydrochloride (DRUG), leucovorin calcium (DRUG), radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00052910?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00052910 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
RECRUITING · Phase 3
-
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
RECRUITING · Phase 3
-
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
RECRUITING · Phase 3
-
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RECRUITING · Phase 3
-
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
ACTIVE NOT RECRUITING · Phase 3
-
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.